Iniparib
Iniparib is a drug that was initially believed to be a PARP inhibitor, which are a group of pharmacological inhibitors of the enzyme called Poly (ADP-ribose) polymerase. It was developed by Sanofi-Aventis for the treatment of various types of cancer, including breast cancer and lung cancer. However, later studies suggested that Iniparib does not work by inhibiting PARP.
History[edit | edit source]
Iniparib was first developed by Sanofi-Aventis, a global pharmaceutical company. It was initially classified as a PARP inhibitor, a type of drug that prevents the repair of DNA damage in cancer cells, thereby leading to their death. Early clinical trials showed promise, particularly in the treatment of triple-negative breast cancer, a subtype of breast cancer that is particularly difficult to treat.
However, later studies, including a Phase III clinical trial, failed to confirm these initial positive results. Furthermore, subsequent research suggested that Iniparib does not function as a PARP inhibitor. The exact mechanism of action of Iniparib remains unclear.
Mechanism of Action[edit | edit source]
The exact mechanism of action of Iniparib is not fully understood. It was initially believed to function as a PARP inhibitor, preventing the repair of DNA damage in cancer cells and thereby leading to their death. However, later research suggested that it does not inhibit PARP.
Despite this, Iniparib has been shown to have anti-cancer effects. It is thought to work by forming toxic adducts with proteins and DNA in cancer cells, leading to their death. However, more research is needed to fully understand how Iniparib works.
Clinical Trials[edit | edit source]
Iniparib has undergone several clinical trials for various types of cancer. Early trials showed promise, particularly for the treatment of triple-negative breast cancer. However, a Phase III clinical trial failed to confirm these initial positive results.
Despite these setbacks, Iniparib continues to be studied for potential use in treating other types of cancer, including lung cancer and ovarian cancer.
See Also[edit | edit source]
 | This pharmacology-related article is a stub. You can help WikiMD by expanding it. |
 | This oncology article is a stub. You can help WikiMD by expanding it. |
 | This medical article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
